Logo

Novartis to Discontinue CIRRUS-1 Study of CFZ533 (iscalimab) in Kidney Transplant Patients

Share this

Novartis to Discontinue CIRRUS-1 Study of CFZ533 (iscalimab) in Kidney Transplant Patients

Shots:

  • The discontinuation is based on the interim analysis of data from the CIRRUS-1 study demonstrating that CFZ533 (iscalimab)-based treatment is less efficacious compared to tacrolimus-based treatment in the prevention of organ rejection in patients receiving a kidney transplant
  • In the study- both CFZ533 and tacrolimus were used in combination with other immunosuppressive therapies (induction therapy- mycophenolate and corticosteroids)
  • The company will continue the study of CFZ533 in liver transplant as the studies are exploring the potential treatment in other conditions- such as hidradenitis suppurativa and Sjögren’s syndrome

Ref: Novartis | Image: Novartis 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions